论文部分内容阅读
目的观察依达拉奉联合奥扎格雷钠治疗进展型脑梗死的疗效及对神经功能缺损和日常生活能力的影响。方法选择急性进展性脑梗死患者90例,随机分为依达拉奉与奥扎格雷钠联合治疗组和奥扎格雷钠单药对照组各45例,治疗疗程共14d。在治疗前、后进行神经功能缺损程度(the nantional institute of health strokescale,NIHSS)、日常生活活动能力(activities of daily living,ADL)和临床疗效的评定。结果治疗组神经功能损害程度评分显著下降,临床疗效显著高于对照组(P<0.05)。两组均无不良反应。结论依达拉奉联合奥扎格雷钠治疗进展性脑梗死有显著疗效,无明显不良反应。
Objective To observe the effect of edaravone and ozagrel sodium in treating progressive cerebral infarction and its effect on neurological deficit and daily living ability. Methods 90 patients with acute progressive cerebral infarction were randomly divided into edaravone and ozagrel sodium combined treatment group and ozagrel sodium single-drug control group of 45 patients for 14 days. The nantional institute of health strokescale (NIHSS), activities of daily living (ADL) and clinical efficacy were assessed before and after treatment. Results The score of neurological impairment in the treatment group decreased significantly, and the clinical effect was significantly higher than that in the control group (P <0.05). No adverse reactions in both groups. Conclusion Edaravone combined with ozagrel sodium in the treatment of progressive cerebral infarction has a significant effect, no significant adverse reactions.